All terms

    EU Medical Device Regulation

    Regulation (EU) 2017/745 governing medical devices in the European Union.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Regulation (EU) 2017/745 (MDR) lays down rules concerning the placing on the market, making available, and putting into service of medical devices for human use and accessories, replacing the previous Medical Devices Directive (MDD).

    What this means in practice

    MDR introduces stricter clinical evidence requirements, stronger post-market surveillance, UDI, EUDAMED registration, and an enhanced role for Notified Bodies. Many devices have undergone reclassification, especially software (Rule 11 pushes most standalone medical software to Class IIa or higher). Transitional provisions extended MDD certificate validity for legacy devices through May 2027 (Class III and implantable Class IIb) and December 2028 (other classes) provided conditions in Regulation (EU) 2023/607 are met.

    Examples

    • A Class IIa mobile app for insulin dose calculation that would have been Class I under the MDD, reclassified under MDR Rule 11.
    • A legacy implantable cardiac device sold under an MDD certificate, extended through May 2027 under the Regulation (EU) 2023/607 transition, with a Notified Body application filed by the required deadline.

    Use cases

    1 scenario
    1

    Class IIb device transitioning from MDD to EU MDR

    Regulatory & Clinical

    The manufacturer expands clinical evaluation, refreshes the technical file to MDR Annex II/III, signs a notified body contract, and registers the device and economic operators in EUDAMED.

    OutcomeCE marking under MDR is issued before the legacy MDD certificate expires, avoiding a supply gap.
    Common pitfalls
    • Assuming Rule 11 does not apply. Most software providing information used for decisions with a diagnostic or therapeutic purpose is now Class IIa or higher.
    • Missing the transition deadlines and Notified Body application windows in Regulation (EU) 2023/607.
    • Under-scoping clinical evidence. MDR expects a Clinical Evaluation Plan and ongoing Post-Market Clinical Follow-up (PMCF), not a one-time literature review.
    • Treating a Person Responsible for Regulatory Compliance (PRRC) role as optional. It is mandatory for manufacturers and authorized representatives.

    Frequently asked questions

    MDR (Regulation (EU) 2017/745) replaced the Medical Devices Directive (93/42/EEC) in 2021. Key changes: stricter clinical evidence, mandatory UDI and EUDAMED registration, reclassification of many devices (especially software under Rule 11), lifecycle post-market surveillance, and a PRRC role.

    Cross-references

    Shared paths + category

    Latest in MedTech

    Primary references

    3 sources
    Link health: 2 verified 1 unchecked· last checked 2026-06-20
    EUR-Lex·2European Commission·1
    1. 1
      Regulation (EU) 2017/745
      Verified
      EUR-Lexeur-lex.europa.eu
    2. 2
      Regulation (EU) 2023/607 (MDR transition extension)
      Unchecked
      EUR-Lexeur-lex.europa.eu
    3. 3
      MDCG Guidance Documents
      Verified
      European Commissionhealth.ec.europa.eu

    Inline markers like [1] jump to the matching reference above.